PortfoliosLab logoPortfoliosLab logo
DNA vs. QSI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DNA vs. QSI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Quantum-Si incorporated (QSI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

The year-to-date returns for both investments are quite close, with DNA having a 12.27% return and QSI slightly higher at 12.73%.


DNA

1D
2.08%
1M
-3.81%
YTD
12.27%
6M
8.61%
1Y
30.86%
3Y*
-47.59%
5Y*
-52.72%
10Y*

QSI

1D
5.08%
1M
29.41%
YTD
12.73%
6M
-2.36%
1Y
-26.19%
3Y*
-9.81%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

DNA vs. QSI - Yearly Performance Comparison


2026 (YTD)20252024202320222021
DNA
Ginkgo Bioworks Holdings, Inc.
12.27%-15.38%-85.47%0.00%-79.66%-16.90%
QSI
Quantum-Si incorporated
12.73%-59.26%34.33%9.84%-76.75%-26.31%

Correlation

The correlation between DNA and QSI is 0.54, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.54

Correlation (3Y)
Calculated over the trailing 3-year period

0.51

Correlation (All Time)
Calculated using the full available price history since Jun 11, 2021

0.50

The correlation between DNA and QSI has been stable across timeframes, ranging from 0.50 to 0.54 - a consistent structural relationship.

Fundamentals

Market Cap

DNA:

$555.73M

QSI:

$268.43M

EPS

DNA:

-$5.40

QSI:

-$0.51

PS Ratio

DNA:

4.32

QSI:

135.06

PB Ratio

DNA:

1.25

QSI:

1.34

Total Revenue (TTM)

DNA:

$121.84M

QSI:

$1.85M

Gross Profit (TTM)

DNA:

$99.27M

QSI:

-$3.71M

EBITDA (TTM)

DNA:

-$218.90M

QSI:

-$104.05M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DNA vs. QSI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA
DNA Risk / Return Rank: 5353
Overall Rank
DNA Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
DNA Sortino Ratio Rank: 5656
Sortino Ratio Rank
DNA Omega Ratio Rank: 5555
Omega Ratio Rank
DNA Calmar Ratio Rank: 5252
Calmar Ratio Rank
DNA Martin Ratio Rank: 5050
Martin Ratio Rank

QSI
QSI Risk / Return Rank: 3131
Overall Rank
QSI Sharpe Ratio Rank: 2828
Sharpe Ratio Rank
QSI Sortino Ratio Rank: 3434
Sortino Ratio Rank
QSI Omega Ratio Rank: 3333
Omega Ratio Rank
QSI Calmar Ratio Rank: 2828
Calmar Ratio Rank
QSI Martin Ratio Rank: 3030
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNA vs. QSI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Quantum-Si incorporated (QSI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


DNAQSIDifference

Sharpe ratio

Return per unit of total volatility

0.31

-0.28

+0.60

Sortino ratio

Return per unit of downside risk

1.14

0.20

+0.94

Omega ratio

Gain probability vs. loss probability

1.14

1.02

+0.12

Calmar ratio

Return relative to maximum drawdown

0.52

-0.36

+0.88

Martin ratio

Return relative to average drawdown

0.90

-0.54

+1.44

DNA vs. QSI - Sharpe Ratio Comparison

The current DNA Sharpe Ratio is 0.31, which is higher than the QSI Sharpe Ratio of -0.28. The chart below compares the historical Sharpe Ratios of DNA and QSI, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


DNAQSIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.31

-0.28

+0.60

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.54

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.54

-0.28

-0.26

Drawdowns

DNA vs. QSI - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum QSI drawdown of -95.33%. Use the drawdown chart below to compare losses from any high point for DNA and QSI.


Loading charts...

Drawdown Indicators


DNAQSIDifference

Max Drawdown

Largest peak-to-trough decline

-99.10%

-95.33%

-3.77%

Max Drawdown (1Y)

Largest decline over 1 year

-66.05%

-72.95%

+6.90%

Max Drawdown (3Y)

Largest decline over 3 years

-94.72%

-83.73%

-10.99%

Max Drawdown (5Y)

Largest decline over 5 years

-99.10%

Current Drawdown

Current decline from peak

-98.44%

-90.86%

-7.58%

Average Drawdown

Average peak-to-trough decline

-79.64%

-79.25%

-0.39%

Ulcer Index

Depth and duration of drawdowns from previous peaks

38.15%

48.24%

-10.09%

Volatility

DNA vs. QSI - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 23.46% compared to Quantum-Si incorporated (QSI) at 21.55%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than QSI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DNAQSIDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.46%

21.55%

+1.91%

Volatility (6M)

Calculated over the trailing 6-month period

70.34%

58.82%

+11.52%

Volatility (1Y)

Calculated over the trailing 1-year period

98.67%

92.59%

+6.08%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

97.66%

125.45%

-27.79%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

96.48%

125.45%

-28.97%

Dividends

DNA vs. QSI - Dividend Comparison

Neither DNA nor QSI has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

DNA vs. QSI - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Quantum-Si incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M202220232024202520260
258.00K
(DNA) Total Revenue
(QSI) Total Revenue
Values in USD except per share items

Frequently Asked Questions


DNA and QSI have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

DNA has higher volatility (23.46%) compared to QSI (21.55%). In terms of maximum drawdown, DNA dropped -99.10% vs QSI's -95.33%.

DNA currently has the higher Sharpe Ratio (0.31 vs -0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DNA and QSI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer